Anti-Human TROP-2 (Sacituzumab) [Clone IMMU-132] (T2030-GRP)

Trophoblast cell surface antigen 2 (TROP-2), also known as tumor-associated calcium signal transducer 2 (TACSTD2), is a cell surface glycoprotein that plays roles in cell-cell adhesion1, cell proliferation, invasion, migration, and apoptosis in healthy tissues as well as tumorigenesis in cancers2. TROP-2 acts as a transmembrane transducer of intracellular calcium signals. In cancer, TROP-2 is necessary and sufficient to drive cancer growth1 and promotes migration and invasion of cancer cells by regulating the calcium ion signaling pathway and cyclin expression, stimulating ERK signaling, and reducing fibronectin adhesion2. TROP-2 stimulates proliferation in some cancers (cervical, bladder) but suppresses proliferation in others (cholangiocarcinoma, MCF7 breast cancer cell lines). TROP-2 is a target for the treatment of advanced metastatic cancers. IMMU-132 (Sacituzumab) is an antibody-drug conjugate developed as an immunotherapy against cancer3. Sacituzumab was developed by site-specific conjugation of SN-38, an irinotecan active metabolite that acts as a DNA topoisomerase I inhibitor, to hRS7, a humanized monoclonal antibody against TROP-2. The original RS7 is a murine monoclonal antibody developed by immunizing mice with cell membranes isolated from squamous non-small cell lung cancer4. SN-38 is covalently linked to hRS7 via a hydrolyzable CL2A linker3. SN-38 is moderately toxic and is conjugated to hRS7 at a high mean drug-to-antibody ratio. Sacituzumab activity is performed. This non-therapeutic biosimilar antibody is not conjugated to SN-38.